Company Profile
Cabaletta Bio Stock Price, News & Catalysts
- Ticker:
- CABA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.58 USD (+3.61%)
Close
Last updated: September 17, 2026
600M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, CABA closed up 3.61% at $2.58. No new same-company headline was identified in the current news window.
Company overview
Autoimmune Cell Therapy Company
Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease.
Rese-cel
Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris.
CARTA Platform
The company’s chimeric antigen receptor T-cell strategy for autoimmunity is designed to eliminate disease-causing B cells and reset the immune system after a single treatment.
Preconditioning-Free Strategy
Cabaletta is evaluating rese-cel without conventional lymphodepleting preconditioning, seeking to simplify treatment and broaden use beyond specialized oncology-style care.
Scalable Manufacturing
A commercial supply agreement with Cellares provides automated manufacturing capacity intended to support treatment of thousands of patients annually.
Future catalysts
- Initiation of the registrational RESET-SSc cohort in systemic-sclerosis-associated interstitial lung disease in the fourth quarter of 2026.
- Registrational RESET-Myositis data in mid-2027.
- Submission of a BLA for rese-cel in myositis in the second half of 2027, subject to supportive data.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cabaletta Bio (CABA)?
Cabaletta Bio (CABA) most recently closed at 2.58 USD, a +3.61% move versus the previous session.
What is the market cap of Cabaletta Bio (CABA)?
Cabaletta Bio currently has a market capitalization of 600M USD on BioPharmSignal.
What does Cabaletta Bio do?
Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease. Rese-cel Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris. CARTA Platform The company’s...
On which exchange is CABA stock listed?
Cabaletta Bio (CABA) is associated with NASDAQ, United States, Biopharma.
What is Autoimmune?
Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease.
Which conditions is Cabaletta Bio targeting with Autoimmune?
Cabaletta Bio is associated with oncology based on its company overview and current catalyst commentary.
How does Cabaletta Bio describe recent progress with Autoimmune?
Initiation of the registrational RESET-SSc cohort in systemic-sclerosis-associated interstitial lung disease in the fourth quarter of 2026. Registrational RESET-Myositis data in mid-2027. Submission of a BLA for rese-cel in myositis in the second half of 2027, subject to supportive data.
What is Cell?
Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease.